DarioHealth (NASDAQ:DRIO) (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.
The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education. Users engage with the mobile application to log measurements, access nutrition and exercise recommendations, and connect with certified health coaches. Employers, health plans, pharmacies and government agencies can license the platform on a subscription basis, enabling large-scale deployment of virtual care programs and population health initiatives.
Headquartered in New York, DarioHealth serves clients across the United States and selected international markets, leveraging partnerships with payors, pharmacy benefit managers and retailer pharmacies. The company’s go-to-market strategy focuses on embedding the Dario solution within existing care pathways, enabling care providers to remotely monitor patient progress, adjust treatment plans and drive adherence.
DarioHealth went public on the NASDAQ under the ticker DRIO in mid-2021 following a business combination with a special purpose acquisition company. Under the leadership of CEO Elad Haramati, PhD, the company continues to expand its digital care offering, pursue new reimbursement pathways and advance its platform through ongoing product development.
